Russell Investments Group Ltd. decreased its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 8.8% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 129,143 shares of the medical research company’s stock after selling 12,492 shares during the period. Russell Investments Group Ltd. owned about 0.16% of Labcorp worth $39,798,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of Labcorp in the third quarter worth $305,000. Banyan Capital Management Inc. acquired a new position in Labcorp during the third quarter valued at $11,755,000. Maryland State Retirement & Pension System raised its position in Labcorp by 13.3% during the third quarter. Maryland State Retirement & Pension System now owns 5,092 shares of the medical research company’s stock valued at $1,569,000 after buying an additional 596 shares during the period. Illinois Municipal Retirement Fund lifted its stake in Labcorp by 4.5% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 49,854 shares of the medical research company’s stock worth $15,361,000 after acquiring an additional 2,163 shares in the last quarter. Finally, Lido Advisors LLC lifted its stake in Labcorp by 365.0% in the 3rd quarter. Lido Advisors LLC now owns 4,673 shares of the medical research company’s stock worth $1,440,000 after acquiring an additional 3,668 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.
Insider Activity at Labcorp
In related news, Director Richelle Parham sold 1,078 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $361.22, for a total value of $389,395.16. Following the completion of the sale, the director owned 2,288 shares of the company’s stock, valued at approximately $826,471.36. The trade was a 32.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Brian Caveney sold 2,000 shares of the stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $372.04, for a total value of $744,080.00. Following the completion of the transaction, the executive vice president owned 34,562 shares in the company, valued at $12,858,446.48. This represents a 5.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,384 shares of company stock valued at $1,241,707. 0.84% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of brokerages have commented on LH. Truist Financial raised their price objective on Labcorp from $365.00 to $395.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. JPMorgan Chase & Co. upped their target price on Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Mizuho set a $355.00 price target on shares of Labcorp in a research report on Monday, August 10th. UBS Group raised their price target on shares of Labcorp from $380.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Finally, Deutsche Bank restated a “hold” rating and set a $355.00 price target on shares of Labcorp in a report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Labcorp currently has a consensus rating of “Moderate Buy” and a consensus target price of $369.08.
Check Out Our Latest Stock Analysis on LH
Labcorp Trading Up 0.5%
NYSE LH opened at $372.38 on Tuesday. The company has a current ratio of 1.41, a quick ratio of 1.22 and a debt-to-equity ratio of 0.60. Labcorp Holdings Inc. has a 1-year low of $245.00 and a 1-year high of $375.10. The firm’s fifty day simple moving average is $330.51 and its 200-day simple moving average is $293.10. The company has a market capitalization of $30.24 billion, a PE ratio of 30.55, a price-to-earnings-growth ratio of 2.10 and a beta of 0.86.
Labcorp (NYSE:LH – Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the firm earned $4.18 earnings per share. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Labcorp Holdings Inc. will post 18.51 earnings per share for the current fiscal year.
Labcorp Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Tuesday, November 24th. Labcorp’s payout ratio is currently 23.63%.
Labcorp Company Profile
Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.
Featured Stories
- Five stocks we like better than Labcorp
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
